News | December 10, 2025
Novo Nordisk completes acquisition of Akero Therapeutics
Akero became a wholly owned subsidiary of Novo Nordisk
Akero became a wholly owned subsidiary of Novo Nordisk
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site marks the company’s first operation in the region
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Expands bioprocessing footprint across Asia
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Subscribe To Our Newsletter & Stay Updated
